A randomized phase 2 trial which investigate the most effective administration method of antithrombin (AT) products in patients with disseminated intravascular coagulation (DIC) associated with sepsis during treatment for advanced pancreatic and biliary cancer.

A randomized phase 2 trial which investigate the most effective administration method of antithrombin (AT) products in patients with disseminated intravascular coagulation (DIC) associated with sepsis during treatment for advanced pancreatic and biliary cancer. - A randomized phase 2 trial of AT-III products in infectious DIC.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015105

Enrollment

Registered

2014-09-10

Start date

2007-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced hepatobiliary and pancreatic cancer patients

Interventions

500 IU of AT-III, 60 min. intravenous infusion, 3 times every 8 hours 1,500 IU of AT-III, 60 min. intravenous infusion in a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) advanced hepatobiliary and pancreatic cancer patients 2) acute DIC 3) AT-III activity less than 70% 4) PS 0-2 adults with informed concent with cocuments

Exclusion criteria

Exclusion criteria: pregnat or possible pregnat women

Design outcomes

Primary

Measure	Time frame
AT-III activity after 72 hours	—

Secondary

Measure	Time frame
1) DIC score after 72 hours 2) DIC score after 7 days 3) SIRS score after 72 hours 4) pyrexia rate at the time of 24 hours and 72 hours later	—

Countries

Japan

Contacts

Public ContactTatsuya Ioka

Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology

ioka-ta@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026